论文部分内容阅读
目的观察Quinimax对非洲恶性疟疾的临床疗效。方法用法国生产Quinimax静脉注射治疗非洲恶性疟疾213例。同时用国产蒿甲醚胶囊口服治疗恶性疟疾213例进行疗效比较,5d1疗程。结果Quinimax组治疗有效率100%,其中临床治愈率56.3%,显效率43.7%,血内疟原虫清除率56.3%。复燃4.2%;蒿甲醚胶囊组治疗有效率100%,其中临床治愈率71.4%,显效率28.6%,血内疟原虫清除率71.4%。复燃5.6%。两组临床治愈率比较差异具显著性(P<0.01);血内疟原虫清除率比较差异具显著性(P<0.01)。Quinimax组对疟原虫血内清除率低于蒿甲醚胶囊组差异具显著性(P<0.01)。结论Quinimax和蒿甲醚胶囊对非洲黑人恶性疟疾的治疗均具有相当高的临床疗效,但5d疗法Quinimax对疟原虫血内清除率较低,该地区恶性疟疾对Quinimax可能产生了抗药性。
Objective To observe the clinical efficacy of Quinimax against malaria in Africa. Methods 213 cases of African malaria were treated with Quinimax intravenous injection in France. At the same time with domestic artemether capsules oral treatment of 213 cases of malaria compared efficacy, 5d1 course of treatment. Results The effective rate of Quinimax group was 100%. The clinical cure rate was 56.3%, markedly effective rate was 43.7% and the blood plasmodium clearance rate was 56.3%. Rekindled 4.2%; artemether capsules treatment efficiency of 100%, of which clinical cure rate was 71.4%, markedly effective rate of 28.6%, blood Plasmodium clearance rate of 71.4%. Resurgence 5.6%. There was significant difference between the two groups in the clinical cure rate (P <0.01), and the difference in the clearance rate of Plasmodium was significant (P <0.01). The blood clearance rate of Plasmodium in the Quinimax group was lower than that in the artemether capsule group (P <0.01). Conclusion Both Quinimax and Artemether capsules have a very high clinical efficacy in the treatment of African black malaria. However, the Quinimax 5-day therapy has a lower clearance rate of Plasmodium, and the malaria in this area may be resistant to Quinimax.